| scholarly article | Q13442814 |
| P50 | author | Antonio Addis | Q38359712 |
| Carlotta Rossi | Q45348356 | ||
| Guido Bertolini | Q45348369 | ||
| P2093 | author name string | Sergio Livigni | |
| Daniele Poole | |||
| Abramo Anghileri | |||
| P2860 | cites work | Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine | Q22306067 |
| Severe sepsis epidemiology: sampling, selection, and society | Q24801309 | ||
| Efficacy and safety of recombinant human activated protein C for severe sepsis | Q29547839 | ||
| A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study | Q29615430 | ||
| Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial | Q30788622 | ||
| New strategies for clinical trials in patients with sepsis and septic shock | Q34261776 | ||
| Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death | Q34455153 | ||
| Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. | Q34480866 | ||
| 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. | Q35094247 | ||
| Under-reporting of adverse drug reactions : a systematic review | Q36475336 | ||
| Activated protein C: do more survive? | Q43571549 | ||
| Continuous quality improvement in intensive care medicine. The GiViTI Margherita Project - Report 2005. | Q45102901 | ||
| Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. | Q51723077 | ||
| Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment* | Q64126934 | ||
| Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial | Q81332049 | ||
| Prescribing indications based on successful clinical trials in sepsis: a difficult exercise | Q82313872 | ||
| P433 | issue | 3 | |
| P921 | main subject | Italy | Q38 |
| drotrecogin alfa | Q412888 | ||
| P304 | page(s) | 426-434 | |
| P577 | publication date | 2007-02-15 | |
| P1433 | published in | Intensive Care Medicine | Q15749164 |
| P1476 | title | Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey | |
| P478 | volume | 33 |
| Q42067556 | An update on activated protein C (xigris) in the management of sepsis |
| Q36987136 | Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis |
| Q21195024 | Clinical trials in severe sepsis with drotrecogin alfa (activated) |
| Q48006853 | Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis |
| Q34370297 | Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. |
| Q36112774 | Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated). |
| Q37142684 | Dissociation of activated protein C functions by elimination of protein S cofactor enhancement |
| Q85950731 | Drotrecogin alfa (activated) in severe sepsis--authors' reply |
| Q36749140 | Drotrecogin alfa (activated): real-life use and outcomes for the UK |
| Q36981698 | Drotrecogin alpha (activated): the treatment for severe sepsis? |
| Q82224648 | Editors' comments on a new trial of activated protein C for persistent septic shock |
| Q34343213 | Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression |
| Q37867315 | Evaluation and management of shock States: hypovolemic, distributive, and cardiogenic shock |
| Q36919457 | Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center |
| Q37106071 | Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy |
| Q37354434 | Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies |
| Q24201123 | Human recombinant activated protein C for severe sepsis |
| Q24235181 | Human recombinant activated protein C for severe sepsis |
| Q24202128 | Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients |
| Q33293620 | Impact of introducing multiple evidence-based clinical practice protocols in a medical intensive care unit: a retrospective cohort study |
| Q36642123 | Increased bleeding risk associated with the use of recombinant human activated protein C in patients with advanced liver disease |
| Q55043389 | Increasing evidence that the risks of rhAPC may outweigh its benefits. |
| Q80467290 | Is there increasing evidence that the risks of rhAPC may outweigh its benefits? |
| Q82224661 | Once is not enough: clinical trials in sepsis |
| Q49505268 | Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis |
| Q33378616 | Practical aspects of treatment with drotrecogin alfa (activated) |
| Q38126264 | Protein C and acute inflammation: a clinical and biological perspective |
| Q36392485 | Recently published papers: therapies failed, disputed, and beneficent |
| Q80467286 | Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions |
| Q34994107 | Scientific and clinical challenges in sepsis |
| Q38058499 | Stopping trials early for benefit--not so fast! |
| Q24644984 | Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 |
| Q34981434 | The efficacy of activated protein C for the treatment of sepsis: incorporating observational evidence with a Bayesian approach |
| Q37279933 | The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes |
| Q36438845 | The safety profile of drotrecogin alfa (activated). |
| Q37129287 | Update in critical care 2007. |
| Q42646236 | Visiting policies in Italian intensive care units: a nationwide survey |
| Q39370623 | Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills? |
| Q37072471 | Year in review in Intensive Care Medicine, 2007. II. Haemodynamics, pneumonia, infections and sepsis, invasive and non-invasive mechanical ventilation, acute respiratory distress syndrome |
Search more.